Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

2-Hydroxyoleic acid - Laminar Pharmaceuticals

Next Previous
Drug Profile

2-Hydroxyoleic acid - Laminar Pharmaceuticals

Alternative Names: 2-hydroxy-9-cis octadecenoic - Laminar Pharmaceuticals; 2-OHOA - Laminar Pharmaceuticals; LAM-561; LP561A1; Minerval

Latest Information Update: 25 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of the Balearic Islands
  • Developer Dana-Farber Cancer Institute; Hackensack Meridian Health; Laminar Pharmaceuticals
  • Class Anorectics; Antineoplastics; Oleic acids
  • Mechanism of Action Furin inhibitors; Notch signalling pathway inhibitors; Phosphatidylcholine ceramide phosphocholine transferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Glioblastoma
  • Phase I/II Glioma; Solid tumours

Most Recent Events

  • 14 Apr 2023 Pharmacodynamics data from a phase IIb/III trial in Glioblastoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 14 Oct 2022 Laminar Pharmaceuticals plans to launch 2-Hydroxyoleic acid for Glioma (In adults) in 2024 (Laminar Pharmaceuticals pipeline, October 2022)
  • 14 Oct 2022 Laminar Pharmaceuticals plans to launch 2-Hydroxyoleic acid for Glioma in 2025 or 2026 (Laminar Pharmaceuticals pipeline, October 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top